Anti-Nivolumab (Opdivo®) (Human) ELISA Kit

Product Overview

A Sandwich ELISA kit for the qualitative determination of antibody against Nivolumab in human serum or plasma.

Nivolumab (Opdivo®) is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the programmed cell death 1 (PD-1) receptor and selectively blocks interaction with its programmed death ligands PD-L1 and PD-L2. Upregulation of PD-1 ligands occurs in some tumors and signalling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumour tissue. The inhibitory effect of PD-1 and its ligands occurs through the promotion of apoptosis in antigen specific T cells while simultaneously blocking apoptosis in suppressor T cells. Blocking PD-1 activity has been shown to lead to decreased tumour growth in mouse tumour models. However, some patients develop unwanted immunogenicity, which leads to production of anti-drug-antibodies (ADAs) inactivating the therapeutic effects of the treatment and, in rare cases, inducing adverse effects. 96Trace’s BioSimTM anti-Nivolumab ELISA kit is designed to detect antibody against Nivolumab with high specificity and sensitivity in biological matrices.

Assay Information

Applications

This ELISA kit is used for Qualitative determination of antibody against Nivolumab (Opdivo) in serum and plasma

Features & Benefits

• Easy, convenient, sensitive and time-saving method toqualitative determination of antibody against Nivolumab (Opdivo) in human serum and plasma.
• Cross Reactivity: Nivolumab (Opdivo®) infusion camouflages/masks the presence of antibody to Nivolumab (ATN) in serum/plasma samples. Therefore, blood sampling time is critical for detection of ATN. It is convenient to obtain blood sample just before the infusion or at least 2 weeks after the infusion of Nivolumab.

Storage & Shipping

Product Details